HAE Документы SEC - Haemonetics Corporation- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

LEI	549300ZEL6TXZS6F5F95
CIK	313143

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Haemonetics Corporation

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

August 7, 2025	EX-10.1	HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT Exhibit 10.1 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (as amend
August 7, 2025	EX-99.1	Haemonetics Reports First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guid
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 HAEMONETICS CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 28, 2025 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as s
July 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 HAEMONETICS CORPORA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
June 6, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.
June 6, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement x Definitive Additional Materials ☐ Soliciting Material under §240.
May 27, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdicti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri
May 27, 2025	EX-1.01	Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2024 to December 31, 2024 Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2024 to December 31, 2024 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2024 to December 31, 2024 pursuant to Rule 13p-1 (“Rule 13p-1”) promulgated under the Securities Exchange Act of 1934
May 21, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 29, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact n
May 21, 2025	EX-21.1	Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Advanced Cooling Therapy, LLC Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics Asia Incorporated Delaware Hae
May 8, 2025	EX-99.1	Haemonetics Reports Fourth Quarter and Fiscal 2025 Results; Provides Fiscal 2026 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2025 Results; Provides Fisca
May 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 HAEMONETICS CORPORATI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissio
March 3, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
March 3, 2025	EX-99.1	Haemonetics Announces Executive Leadership Updates Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial Officer Exhibit 99.1 Investor Contacts: Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Senior Director-Global Communications (781) 356-9776 [email protected] Haemonetics Announces Executive Leadership Updates Frank Chan joins H
February 6, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
February 6, 2025	EX-99.1	Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2025 Results; Updates Fiscal 2025 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2025 Results; Updates F
February 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 28, 2024 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant
January 14, 2025	EX-99.1	Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A Exhibit 99.1 Investor Contacts: Media Contact: Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 [email protected] Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A BOSTON, J
January 14, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
January 3, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Com
December 3, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
December 3, 2024	EX-99.1	Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A Exhibit 99.1 Investor Contacts: Media Contact: Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 [email protected] Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A BOSTON, D
November 12, 2024	SC 13G/A	HAE / Haemonetics Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
November 8, 2024	SC 13G/A	HAE / Haemonetics Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
November 8, 2024	EX-99	JOINT FILING AGREEMENT EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Haemonetics Corporation is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k
November 7, 2024	EX-99.1	Haemonetics Reports Second Quarter and First Half Fiscal 2025 Results; Updates Fiscal 2025 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Second Quarter and First Half Fiscal 2025 Results; Updates Fi
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 28, 2024 ☐ TRANSITION REPORT PURSUAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
September 16, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Co
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 29, 2024 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as s
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
August 8, 2024	EX-99.1	Haemonetics Reports First Quarter Fiscal 2025 Results; Reaffirms Fiscal 2025 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports First Quarter Fiscal 2025 Results; Reaffirms Fiscal 2025 Guid
July 30, 2024	8-K/A	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi
July 25, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
June 7, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.
June 7, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement x Definitive Additional Materials ☐ Soliciting Material under §240.
May 29, 2024	EX-10.1	Form of Confirmation of Base Call Option Transaction. Exhibit 10.1 [Dealer] [] [] Attention: [] Telephone No.: [] Facsimile No.: [] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Michelle Basil, General Counsel Telephone No.: Email: From: Re: Base Call Option Transaction Date: May 22, 2024 Dear Ladies and Gentlemen: The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions
May 29, 2024	EX-10.2	Form of Confirmation of Additional Call Option Transaction. Exhibit 10.2 [Dealer] [] [] Attention: [] Telephone No.: [] Facsimile No.: [] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Michelle Basil, General Counsel Telephone No.: Email: From: Re: Additional Call Option Transaction Date: May 23, 2024 Dear Ladies and Gentlemen: The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and condi
May 29, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of
May 29, 2024	EX-4.1	Indenture, dated as of May 28, 2024, between Haemonetics Corporation and U.S. Bank National Association, as trustee. Exhibit 4.1 Haemonetics Corporation and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of May 28, 2024 2.50% Convertible Senior Notes due 2029 TABLE OF CONTENTS Page Article 1.     Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 12 Section 1.03. Rules of Construction 13 Article 2.    The Notes 14 Section 2.01. Form, Dati
May 28, 2024	EX-1.01	Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2023 to December 31, 2023 Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2023 to December 31, 2023 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2023 to December 31, 2023 pursuant to Rule 13p-1 (“Rule 13p-1”) promulgated under the Securities Exchange Act of 1934
May 28, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdicti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri
May 23, 2024	EX-99.1	Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 [email protected] [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senio
May 23, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of
May 21, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of
May 21, 2024	EX-99.1	Haemonetics Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 [email protected] [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Announces Proposed Convertible Senior Notes Offering BOSTON, MA, M
May 20, 2024	EX-10.41	ADDENDA NO 2 Adresse des lieux loues 750, boulevard du Parc Technologique Québec (Québec) G1P 4S3 Page 1 s ADDENDA NO 2 Adresse des lieux loues 750, boulevard du Parc Technologique Québec (Québec) G1P 4S3 ENTRE: 1405 PTQM S.
May 20, 2024	EX-21.1	Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Advanced Cooling Therapy, Inc. Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics Asia Incorporated Delaware Ha
May 20, 2024	EX-97.1	HAEMONETICS CORPORATION COMPENSATION RECOVERY POLICY Exhibit 97.1 HAEMONETICS CORPORATION COMPENSATION RECOVERY POLICY Haemonetics Corporation, a Massachusetts corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in acco
May 20, 2024	EX-10.40	[ADDENDA NO 1] Adresse des lieux loues 750, boulevard du Parc Technologique Québec (Québec) G1P 4S3 Page 1 [ADDENDA NO 1] Adresse des lieux loues 750, boulevard du Parc Technologique Québec (Québec) G1P 4S3 ENTRE : 1405 PTQM S.
May 20, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact n
May 20, 2024	EX-10.39	BAIL 1405 PTQM (SEC) (ci-après le « Bailleur ») Opsens Inc. (ci-après le « Locataire ») Adresse des Lieux loues : 750,.boulevard du Parc Technologique Québec (Québec) G1P 4S3 Échéance du terme du bail ; 30 septembre·2025 Page 1 BAIL ENTRE 1405 PTQM (SEC) (ci-après le « Bailleur ») ET Opsens Inc. (ci-après le « Locataire ») Adresse des Lieux loues : 750,.boulevard du Parc Technologique Québec (Québec) G1P 4S3 Échéance du terme du bail ; 30 septembre·2025 Page 2 TABLE DES MATIÈRES 1. INTENTION DES PARTIES 4 2. IMMEUBLE 4 3. LIEUX LOUES 5 4. DURÉE DE LOCATION 5 5. USAGE 5 6. OCCUPATION 5 7. NON RELOCALISATION 5 8. LO
May 20, 2024	EX-19.1	HAEMONETICS CORPORATION SECURITIES TRADING POLICY Exhibit 19.1 HAEMONETICS CORPORATION SECURITIES TRADING POLICY 1.Purpose This Securities Trading Policy (this “Policy”) sets forth the guidelines of Haemonetics Corporation and its subsidiaries (collectively, “Haemonetics”) regarding compliance with U.S. and foreign securities laws and regulations relating to trading in Haemonetics and third-party securities. The purpose of this Policy is to promo
May 9, 2024	EX-99.1	Haemonetics Reports Fourth Quarter and Fiscal 2024 Results; Provides Fiscal 2025 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2024 Results; Provides Fiscal 2025 Guidan
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissio
May 1, 2024	EX-10.1	Second Amended and Restated Credit Agreement, dated as of April 30, 2024, by and among the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent Exhibit 10.1 EXECUTION VERSION SECOND AMENDED AND RESTATED CREDIT AGREEMENT dated as of April 30, 2024 among HAEMONETICS CORPORATION The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., BofA SECURITIES, INC., CITIBANK, N.A., CITIZENS BANK, N.A., PNC CAPITAL MARKETS LLC, TRUIST SECURITIES, INC., U.S. BANK NATIONAL ASSOCIATION and WELLS FARGO SEC
May 1, 2024	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
April 1, 2024	EX-99.1	Haemonetics Corporation Completes Acquisition of Attune Medical Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Corporation Completes Acquisition of Attune Medical BOSTON, April
April 1, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
March 5, 2024	EX-99.1	Haemonetics Announces Definitive Agreement to Acquire Attune Medical Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Announces Definitive Agreement to Acquire Attune Medical BOSTON, M
March 5, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
February 13, 2024	SC 13G/A	HAE / Haemonetics Corporation / Neuberger Berman Group LLC Passive Investment SC 13G/A 1 formsc13ga-02132024080223.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* HAEMONETICS CORP (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
February 13, 2024	SC 13G/A	HAE / Haemonetics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01063-haemoneticscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 14)* Name of issuer: Haemonetics Corp Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate
February 9, 2024	SC 13G/A	HAE / Haemonetics Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
February 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 30, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant
February 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
February 8, 2024	EX-10.3	SIXTH AMENDMENT TO LEASE AGREEMENT CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
February 8, 2024	SC 13G/A	HAE / Haemonetics Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo
February 8, 2024	EX-99.1	Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2024 Results; Updates Fiscal 2024 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2024 Results; Updates Fiscal
February 8, 2024	EX-10.4	125 SUMMER STREET BOSTON, MA OFFICE LEASE AGREEMENT OPG 125 SUMMER OWNER (DE) LLC, a Delaware limited liability company, AS LANDLORD HAEMONETICS CORPORATION, a Massachusetts corporation, AS TENANT OFFICE LEASE AGREEMENT TABLE OF CONTENTS CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
December 12, 2023	EX-99.1	Haemonetics Corporation Completes Acquisition of OpSens Inc. Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Corporation Completes Acquisition of OpSens Inc. Boston, MA, Decem
December 12, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Com
November 2, 2023	EX-99.1	Haemonetics Reports Second Quarter and First Half Fiscal 2024 Results; Updates Fiscal 2024 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Second Quarter and First Half Fiscal 2024 Results; Updates Fiscal 2
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant
November 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
October 12, 2023	EX-2.1	CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [*]. HAEMONETICS CORP Exhibit 2.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [*]. HAEMONETICS CORPORATION and 9500-7704 QUÉBEC INC. and OPSENS INC. ARRANGEMENT AGREEMENT October 10, 2023 11633442v2 TABLE OF CONTENTS Article 1 INTERPRETA
October 12, 2023	EX-10.1	CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [*]. VOTING SUPPORT A Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [*]. VOTING SUPPORT AGREEMENT THIS AGREEMENT is made as of October 10, 2023 BETWEEN: [NAME], an individual resident in [●] (the “Shareholder”) - and - 9500-77
October 12, 2023	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of
October 10, 2023	EX-99.1	Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc. Expands Haemonetics’ Hospital portfolio with innovative fiber optic sensor technology for interventional cardiology Significant commercial synergies with Haemonetics’ exis Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.
October 10, 2023	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
August 11, 2023	S-8	As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No.
August 11, 2023	EX-24.1	POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that each of the undersigned, being a director or officer, or both, of Haemonetics Corporation (the “Company”), constitutes and appoints Christopher A. Simon, President and Chief Executive Officer, and Michelle L. Basil, Executive Vice President and General Counsel, and each of them, his or her true and lawful attorneys-in-fact and
August 11, 2023	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 (Form Type) Haemonetics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Haemonetics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Proposed Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, $0.
August 8, 2023	EX-10.3	HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT Exhibit 10.3 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT This NONQUALIFIED STOCK OPTION AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (as
August 8, 2023	EX-10.1	Haemonetics Corporation Worldwide Employee Bonus Plan (As Amended and Restated Effective May 13, 2023) Exhibit 10.1 Haemonetics Corporation Worldwide Employee Bonus Plan (As Amended and Restated Effective May 13, 2023) 1.Background and Purpose. 1.1Purpose. The purpose of the Haemonetics Corporation Worldwide Employee Bonus Plan (the “Plan”) is to provide incentive compensation to those eligible employees with significant responsibility for the growth, profitability and success of the Company’s busi
August 8, 2023	EX-10.2	HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.2 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (as amended
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 1, 2023 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 1, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as sp
August 8, 2023	EX-10.4	HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT Exhibit 10.4 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (as amend
August 8, 2023	EX-99.1	Haemonetics Reports First Quarter Fiscal 2024 Results; Updates Fiscal 2024 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports First Quarter Fiscal 2024 Results; Updates Fiscal 2024 Guidance Bos
August 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
August 7, 2023	EX-10.1	HAEMONETICS CORPORATION AMENDED AND RESTATED 2019 LONG-TERM INCENTIVE COMPENSATION PLAN Exhibit 10.1 HAEMONETICS CORPORATION AMENDED AND RESTATED 2019 LONG-TERM INCENTIVE COMPENSATION PLAN Effective as of the Effective Date (as defined below), the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan is hereby amended and restated (as amended and restated, the “Plan”). The purpose of the Plan is to provide employees of Haemonetics Corporation (the “Company”) and its subs
August 7, 2023	EX-99.1	Diane M. Bryant Joins Haemonetics' Board of Directors Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Diane M. Bryant Joins Haemonetics' Board of Directors BOSTON, Aug. 7, 2023 - H
August 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 HAEMONETICS CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
June 16, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro DEFA14A 1 a2023additionalproxymateri.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
June 16, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.
May 30, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdicti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri
May 30, 2023	EX-1.01	Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2022 to December 31, 2022 Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2022 to December 31, 2022 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2022 to December 31, 2022 pursuant to Rule 13p-1 (“Rule 13p-1”) promulgated under the Securities Exchange Act of 1934
May 22, 2023	EX-21.1	Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics Asia Incorporated Delaware Haemonetics Asia UK Ltd. United Kingdom Ha
May 22, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 1, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact na
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 HAEMONETICS CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi
May 11, 2023	EX-99.1	Haemonetics Reports Fourth Quarter and Fiscal 2023 Results; Provides Fiscal 2024 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2023 Results; Provides Fiscal 2024 Guidan
February 13, 2023	SC 13G/A	HAE / Haemonetics Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
February 10, 2023	SC 13G/A	HAE / Haemonetics Corporation / Neuberger Berman Group LLC - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Haemonetics Corp (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
February 9, 2023	SC 13G/A	HAE / Haemonetics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Haemonetics Corp. Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒
February 7, 2023	EX-99.1	Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2023 Results; Updates Fiscal 2023 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2023 Results; Updates Fiscal
February 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
February 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant
February 6, 2023	SC 13G/A	HAE / Haemonetics Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
November 8, 2022	EX-10.2	AMENDMENT II SHELTER PLAN SERVICE AGREEMENT DATED JUNE 10, 2014 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 1, 2022 ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 1, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as
November 7, 2022	EX-99.1	Haemonetics Reports Second Quarter and First Half Fiscal 2023 Results; Updates Fiscal 2023 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports Second Quarter and First Half Fiscal 2023 Results; Updates Fiscal 2023 Guidance Boston, MA, November 7, 2022 - Haemonetics Corporation (NYSE: HAE) repo
November 7, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
October 19, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
October 11, 2022	SC 13G/A	HAE / Haemonetics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0011-haemoneticscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Haemonetics Corp. Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: September 30, 2022 Check the appropriate box to designate
August 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 2, 2022 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 2, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as sp
August 10, 2022	EX-10.2	SUPPLEMENTAL RELEASE OF CLAIMS Exhibit 10.2 June 14, 2022 Michelle Basil c/o Haemonetics Corporation 125 Summer Street Boston, MA 02110 RE: Executive Vice President and General Counsel Retention and Transition Agreement Dear Michelle: This Retention and Transition Agreement (this ?Agreement?) sets forth the understanding between you and Haemonetics Corporation (the ?Company?) regarding your continued employment as Executive Vic
August 10, 2022	EX-99.1	Haemonetics Reports First Quarter Fiscal 2023 Results; Updates Fiscal 2023 Guidance; Announces New $300 Million Share Repurchase Authorization Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports First Quarter Fiscal 2023 Results; Updates Fiscal 2023 Guidance; Announces New $300 Million Share Repurchase Authorization Boston, MA, August 10, 2022
August 10, 2022	EX-10.1	CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
August 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
August 8, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
August 1, 2022	EX-10.1	_____________________________________________________________________________________ AMENDED AND RESTATED CREDIT AGREEMENT dated as of July 26, 2022 HAEMONETICS CORPORATION The Lenders Party Hereto JPMORGAN CHASE BANK, N.A., as Administrative Agent EXECUTION VERSION AMENDED AND RESTATED CREDIT AGREEMENT dated as of July 26, 2022 among HAEMONETICS CORPORATION The Lenders Party Hereto and JPMORGAN CHASE BANK, N.
August 1, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
June 17, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material under ?240.
June 17, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ?240.
June 16, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
May 26, 2022	EX-1.01	Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2021 to December 31, 2021 EX-1.01 2 a2021conflictmineralsrepor.htm EX-1.01 Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2021 to December 31, 2021 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2021 to December 31, 2021 pursuant to Rule 13p-1 (“Rule 13p-1”) prom
May 26, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdicti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri
May 25, 2022	EX-21.1	Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics (UK) Limited United Kingdom Haemonetics Asia Incorporated Delaware Ha
May 25, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 2, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact na
May 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi
May 10, 2022	EX-99.1	Haemonetics Reports Fourth Quarter and Fiscal 2022 Results; Provides Fiscal 2023 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2022 Results; Provides Fiscal 2023 Guidance Boston, MA, May 10, 2022 - Haemonetics Corporation (NYSE: HAE) reported financial
April 8, 2022	SC 13G	HAE / Haemonetics Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) March 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
March 21, 2022	EX-99.1	Haemonetics Appoints James D’Arecca Chief Financial Officer Exhibit 99.1 Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Appoints James D?Arecca Chief Financial Officer Boston, MA, March 21, 2022 - Haemonetics Corporation (NYSE: HAE) today announced that James C. D?Arecca will join the
March 21, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
February 15, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Com
February 14, 2022	SC 13G/A	HAE / Haemonetics Corporation / Neuberger Berman Group LLC - NONE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Haemonetics Corp (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 11, 2022	SC 13G/A	HAE / Haemonetics Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
February 10, 2022	SC 13G/A	HAE / Haemonetics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Haemonetics Corp. Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒
February 10, 2022	SC 13G/A	HAE / Haemonetics Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) January 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 8, 2022	EX-10.1	FOURTEENTH AMENDMENT TO AGREEMENT OF LEASE DATED THIS 11th DAY OF NOVEMBER, 2021 BY AND BETWEEN CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
February 8, 2022	EX-10.2	SUPPLEMENTAL RELEASE OF CLAIMS Exhibit 10.2 November 8, 2021 William P. Burke Address on file with the Company RE: CFO Retention and Transition Agreement Dear Bill: This Retention and Transition Agreement (this ?Agreement?) sets forth the understanding between you and Haemonetics Corporation (the ?Company?) regarding your continued employment as Chief Financial Officer of the Company and your planned retirement from the Company
February 8, 2022	EX-99.1	Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2022 Results; Updates Fiscal 2022 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2022 Results; Updates Fiscal 2022 Guidance Boston, MA, February 8, 2022 - Haemonetics Corporation (NYSE: HAE) reported financial
February 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi
February 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 1, 2022 ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 1, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as
February 4, 2022	SC 13G	HAE / Haemonetics Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
November 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 2, 2021 ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 2, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as
November 9, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi
November 9, 2021	EX-99.2	Haemonetics Announces CFO William P. Burke’s Retirement for June 2022 Exhibit 99.2 Investor Contact Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Announces CFO William P. Burke?s Retirement for June 2022 BOSTON, MA, November 9, 2021 ? Haemonetics Corporation (NYSE: HAE), a global medical technology company focus
November 9, 2021	EX-99.1	Haemonetics Reports Second Quarter and 1st Half Fiscal 2022 Results; Updates Fiscal 2022 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports Second Quarter and 1st Half Fiscal 2022 Results; Updates Fiscal 2022 Guidance Boston, MA, November 9, 2021 - Haemonetics Corporation (NYSE: HAE) reported financial re
August 11, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 3, 2021 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 3, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as sp
August 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
August 11, 2021	EX-99.1	Haemonetics Reports First Quarter Fiscal 2022 Results; Increases Guidance for Vascular Closure Revenue and Affirms All Other Fiscal 2022 Guidance; Expands Operational Excellence Program Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports First Quarter Fiscal 2022 Results; Increases Guidance for Vascular Closure Revenue and Affirms All Other Fiscal 2022 Guidance; Expands Operational Excellence Program
August 9, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
June 17, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material under ?240.
June 17, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appro UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ?240.
June 10, 2021	SC 13G/A	HAE / Haemonetics Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) May 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
May 28, 2021	EX-1.01	Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2020 to December 31, 2020 Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2020 to December 31, 2020 This is the Conflict Mineral Report (?CMR?) of Haemonetics Corporation (?Haemonetics,? ?we,? ?us,? or ?our?) for the reporting period from January 1, 2020 to December 31, 2020 pursuant to Rule 13p-1 (?Rule 13p-1?) promulgated under the Securities Exchange Act of 1934,
May 28, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdicti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri
May 26, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 3, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact na
May 26, 2021	EX-21.1	Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics (UK) Limited United Kingdom Haemonetics Asia Incorporated Delaware Ha
May 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi
May 13, 2021	EX-99.1	Haemonetics Reports Fourth Quarter and Fiscal 2021 Results; Provides Fiscal 2022 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2021 Results; Provides Fiscal 2022 Guidance Boston, MA, May 13, 2021 - Haemonetics Corporation (NYSE: HAE) reported financial results for its
May 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi
April 19, 2021	EX-99.1	HAEMONETICS PROVIDES UPDATE ON U.S. PLASMA BUSINESS Exhibit 99.1 Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, Vice President-Communications (781) 348-7263 [email protected] HAEMONETICS PROVIDES UPDATE ON U.S. PLASMA BUSINESS BOSTON, MA, April 19, 2021 - Haemonetics Corporation (NYSE: HAE) (?Haemonetics? or the ?Company?), a global medical techno
April 19, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
March 16, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction o
March 16, 2021	EX-10.1	Form of Confirmation of Additional Call Option Transaction. Exhibit 10.1 [] [] [] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Telephone No.: Email: From: Re: Additional Call Option Transaction Date: March 12, 2021 Dear Ladies and Gentlemen: The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option transaction entered into between [] (?Dealer?) and Haemonetic
March 5, 2021	EX-10.1	Form of Confirmation of Call Option Transaction. Exhibit 10.1 [] [] [] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Telephone No.: Email: From: Re: Base Call Option Transaction Date: March 2, 2021 Dear Ladies and Gentlemen: The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option transaction entered into between [] (?Dealer?) and Haemonetics Corpo
March 5, 2021	EX-4.1	Indenture, dated as of March 5, 2021, between Haemonetics Corporation and U.S. Bank National Association, as trustee. Exhibit 4.1 Haemonetics Corporation and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of March 5, 2021 0.00% Convertible Senior Notes due 2026 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 13 Article 2. The Notes 14 Section 2.01. Form, Dating and Denominations
March 5, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of
March 3, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of
March 3, 2021	EX-99.1	Haemonetics Prices $435.0 Million Convertible Senior Notes Offering Exhibit 99.1 Haemonetics Prices $435.0 Million Convertible Senior Notes Offering BOSTON, March 2, 2021?Haemonetics Corporation (?Haemonetics?) (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2026 (the ?notes?) in a private offering (the ?offering?) to qualified institutional buyers pursuant to Rule 144A under
March 1, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of
March 1, 2021	EX-10.1	Amendment No. 1, dated as of March 1, 2021, to Credit Agreement dated as of June 15, 2018, by and among Haemonetics Corporation, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent Exhibit 10.1 AMENDMENT NO. 1 Dated as of March 1, 2021 to CREDIT AGREEMENT Dated as of June 15, 2018 THIS AMENDMENT NO. 1 (this ?Amendment?) is made as of March 1, 2021 by and among HAEMONETICS CORPORATION, a Massachusetts corporation (the ?Company?), the financial institutions listed on the signature pages hereof as ?Term A-2 Lenders?, the existing Lenders (immediately prior to the effectiveness
March 1, 2021	EX-99.1	Haemonetics Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 Haemonetics Announces Proposed Convertible Senior Notes Offering BOSTON, March 1, 2021—Haemonetics Corporation (“Haemonetics”) (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $425,000,000 aggregate principal amount of Convertible Senior Notes due 2026 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers purs
February 16, 2021	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Haemonetics Corp (Name of Issuer) (Title of Class of Securities) (CUSIP Number) December 31, 2020 (Date Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Haemonetics Corp (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Haemonetics Corp. Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒
February 2, 2021	EX-10.2	TWELFTH AMENDMENT TO AGREEMENT OF LEASE DATED THIS 22nd DAY OF MAY, 2020 BY AND BETWEEN CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
February 2, 2021	EX-99.1	Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2021 Results Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2021 Results Boston, MA, February 2, 2021 - Haemonetics Corporation (NYSE: HAE) reported financial results for its third quarter a
February 2, 2021	EX-10.3	THIRTEENTH AMENDMENT TO AGREEMENT OF LEASE DATED THIS 21st DAY OF DECEMBER, 2020 BY AND BETWEEN CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
February 2, 2021	EX-10.1	FIRST AMENDMENT TO LEASE AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (“Amendment”) is entered into this 1st day of October, 2020, by and between CLINTON COMMERCE III, LLC, a Pennsylvania limited liability company ("Landlord"), and HAEMONETICS CORPORATION, a Massachusetts corporation ("Tenant"). WITNESSETH: WHEREAS, Landlord and Tenant entered into that certain Industrial Lease A
February 2, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi
February 2, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 26, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant
February 2, 2021	EX-10.4	AGREEMENT AND PLAN OF MERGER by and among HAEMONETICS CORPORATION; CONCORDIA MERGER SUB, INC.; CARDIVA MEDICAL, INC.; FORTIS ADVISORS LLC, as the Seller Representative Dated as of January 17, 2021 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
January 20, 2021	EX-99.1	HAEMONETICS TO ACQUIRE CARDIVA MEDICAL, INC. TO EXPAND HOSPITAL PORTFOLIO Exhibit 99.1 Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, Vice President-Communications (781) 348-7263 [email protected] HAEMONETICS TO ACQUIRE CARDIVA MEDICAL, INC. TO EXPAND HOSPITAL PORTFOLIO •Enhances penetration into the large and growing interventional cardiology and electrophysiology mar
January 20, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
November 10, 2020	SC 13G/A	HAE / Haemonetics Corp. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) October 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched
November 4, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
November 4, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 26, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant
November 4, 2020	EX-99.1	Haemonetics Reports Second Quarter and 1st Half Fiscal 2021 Results Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports Second Quarter and 1st Half Fiscal 2021 Results Boston, MA, November 4, 2020 - Haemonetics Corporation (NYSE: HAE) reported financial results for its second quarter and
September 18, 2020	8-K	Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Co
August 4, 2020	EX-99.1	Haemonetics Reports First Quarter Fiscal 2021 Results Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports First Quarter Fiscal 2021 Results Boston, MA, August 4, 2020 - Haemonetics Corporation (NYSE: HAE) reported financial results for its first quarter of fiscal 2021, whic
August 4, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
August 4, 2020	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of in
August 4, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 27, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as s
August 4, 2020	EX-10.1	INDUSTRIAL LEASE AGREEMENT CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
August 4, 2020	EX-99.1	Haemonetics Reports First Quarter Fiscal 2021 Results Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports First Quarter Fiscal 2021 Results Boston, MA, August 4, 2020 - Haemonetics Corporation (NYSE: HAE) reported financial results for its first quarter of fiscal 2021, whic
July 24, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
July 24, 2020	EX-99.1	HAEMONETICS ANNOUNCES SALE OF INLOG HOLDINGS FRANCE SAS TO ABÉNEX CAPITAL Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, VP- Global Communications (781) 348-7263 [email protected] FOR IMMEDIATE RELEASE HAEMONETICS ANNOUNCES SALE OF INLOG HOLDINGS FRANCE SAS TO ABÉNEX CAPITAL BOSTON, MA, July 24, 2020 - Haemonetics Corporation (NYSE: HAE), a global medical technology co
July 2, 2020	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi
July 1, 2020	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi
June 30, 2020	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
June 30, 2020	EX-3.2	ARTICLE IV Place of Shareholders’ Meetings Exhibit 3.2 The amendments to the Company’s By-Laws effective June 29, 2020 are set forth below. Text stricken through indicates deletions, and text that is underlined indicates additions. ARTICLE IV Place of Shareholders’ Meetings All meetings of the shareholders shall be held either or both (a) at the principal office of the Corporation in Massachusetts, unless a different place within Massachus
June 30, 2020	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
June 30, 2020	EX-3.1	HAEMONETICS CORPORATION ARTICLE I Articles of Organization Exhibit 3.1 As amended through June 29, 2020 BY-LAWS of HAEMONETICS CORPORATION ARTICLE I Articles of Organization The name and purposes of the Corporation shall be as set forth in the Articles of Organization. These By-Laws, the powers of the Corporation and of its Directors and shareholders, and all matters concerning the conduct and regulation of the business of the Corporation shall be subject
June 30, 2020	EX-99.1	HAEMONETICS ANNOUNCES 2020 ANNUAL MEETING OF SHAREHOLDERS WILL BE CONDUCTED IN VIRTUAL FORMAT Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, VP-Global Communications (781) 348-7263 [email protected] HAEMONETICS ANNOUNCES 2020 ANNUAL MEETING OF SHAREHOLDERS WILL BE CONDUCTED IN VIRTUAL FORMAT BOSTON, MA, June 30, 2020 - Haemonetics Corporation (NYSE: HAE)
June 30, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement x Definitive Additional Materials ☐ Soliciting Material under §240.
June 11, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss
June 11, 2020	EX-99.1	HAEMONETICS ANNOUNCES BLOOD FILTER SUPPLY AGREEMENT AND SALE OF PUERTO RICO-BASED MANUFACTURING OPERATIONS TO GVS S.p.A Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, VP- Global Communications (781) 348-7263 [email protected] HAEMONETICS ANNOUNCES BLOOD FILTER SUPPLY AGREEMENT AND SALE OF PUERTO RICO-BASED MANUFACTURING OPERATIONS TO GVS S.p.A BOSTON, MA, June 3, 2020 - Haemoneti
June 8, 2020	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.
June 8, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement x Definitive Additional Materials ☐ Soliciting Material under §240.
May 29, 2020	SD	- SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri
May 29, 2020	EX-1.01	Exhibit 1.01 Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2019 to December 31, 2019 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2019 to December 31, 2019 pursuant to Rule 13p-1 (“Rule 13p-1”) promulgated under the Securities Exchange Act of 1934
May 28, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi
May 28, 2020	EX-99.1	HAEMONETICS ANNOUNCES SALE OF U.S. BLOOD DONOR MANAGEMENT SOFTWARE SOLUTION ASSETS TO THE GPI GROUP Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, VP-Communications (781) 348-7263 [email protected] HAEMONETICS ANNOUNCES SALE OF U.S. BLOOD DONOR MANAGEMENT SOFTWARE SOLUTION ASSETS TO THE GPI GROUP BOSTON, MA, May 28, 2020 - Haemonetics Corporation (NYSE: HAE),
May 20, 2020	EX-4.B	Exhibit 4B EXHIBIT 4B DESCRIPTION OF REGISTRANT’S COMMON STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 28, 2020, Haemonetics Corporation (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): shares of Common Stock, $0.
May 20, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 28, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact n
May 20, 2020	EX-21.1	Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Arryx, Inc. Nevada Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics (UK) Limited United Kingdom Haemonetics Asia Incorporated Delaware Haemonetics Asia UK Ltd. United K
May 5, 2020	EX-99.1	Haemonetics Reports 4th Quarter and Fiscal 2020 Results; Provides Update on Business Continuity and Impacts from COVID-19 Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports 4th Quarter and Fiscal 2020 Results; Provides Update on Business Continuity and Impacts from COVID-19 Boston, MA, May 5, 2020 - Haemonetics Corporation (NYSE: HAE) repo
May 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissio
April 17, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
April 17, 2020	EX-99.1	Michael Coyle Joins Haemonetics Board of Directors For Immediate Release Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 olga.
April 9, 2020	SC 13G/A	HAE / Haemonetics Corp. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) March 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
March 4, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Com
February 14, 2020	SC 13G	HAE / Haemonetics Corp. / Neuberger Berman Group LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Haemonetics Corp (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
February 12, 2020	SC 13G/A	HAE / Haemonetics Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Haemonetics Corp Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru
February 4, 2020	EX-99.1	Haemonetics Reports 3rd Quarter and Year-to-Date Fiscal 2020 Results; Reaffirms Revenue Guidance and Raises All Other Guidance for Fiscal 2020 Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports 3rd Quarter and Year-to-Date Fiscal 2020 Results; Reaffirms Revenue Guidance and Raises All Other Guidance for Fiscal 2020 Boston, MA, February 4, 2020 - Haemonetics Co
February 4, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant
February 4, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
January 27, 2020	SC 13G/A	HAE / Haemonetics Corp. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
January 14, 2020	EX-99.1	HAEMONETICS ANNOUNCES ACQUISITION OF INTELLECTUAL PROPERTY ASSETS RELATING TO TEG® 6S HEMOSTASIS ANALYZER SYSTEM FOR IMMEDIATE RELEASE Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 olga.
January 14, 2020	8-K	Regulation FD Disclosure, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
November 1, 2019	EX-99.1	Haemonetics Reports 2nd Quarter and 1st Half Fiscal 2020 Results; Raises Fiscal 2020 Adjusted Operating Margin and Adjusted EPS Guidance Exhibit 99.1 Earnings Release FY20 Q2 Investor Contact Media Contact Olga Guyette, Sr. Mgr.-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports 2nd Quarter and 1st Half Fiscal 2020 Results; Raises Fiscal 2020 Adjusted Operating Margin and Adjusted EPS Guidance Braintree, MA, November 1,
November 1, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2019 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm
November 1, 2019	EX-10.6	LEASE ARTICLE 1 Reference Information EXHIBIT 10.6 LEASE ARTICLE 1 Reference Information 1.1 Reference Information. Reference in this Lease to any of the following shall have the meaning set forth below: Effective Date: August 26, 2019. Lot: Premises: The parcel of land known as 400 Wood Road, Braintree, Massachusetts, more particularly described on Exhibit A attached hereto. The building situated on the Lot (the “Building”). Landlord
November 1, 2019	EX-10.4	HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT EXHIBIT 10.4 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT This NONQUALIFIED STOCK OPTION AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (th
November 1, 2019	EX-10.2	HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT EXHIBIT 10.2 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (the “Plan”
November 1, 2019	EX-10.5	HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT EXHIBIT 10.5 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (the “Pla
November 1, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant
November 1, 2019	EX-10.3	HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT EXHIBIT 10.3 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (the “Plan”
August 30, 2019	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2019 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi
August 6, 2019	EX-99.1	Haemonetics Reports 1st Quarter Fiscal 2020 Results, Updates Fiscal 2020 Earnings Guidance and Launches Operational Excellence Program Exhibit 99.1 Earnings Release FY20 Q1 Investor Contacts Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 [email protected] [email protected] Olga Vlasova, Sr. Mgr.-Investor Relations (781) 356-9763 [email protected] Haemonetics Reports 1st Quarter Fiscal 2020 Results, Updates Fiscal 2020 Earnings Gu
August 6, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis
August 6, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 29, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as s
July 30, 2019	POS AM	Post-Effective Amendment to Form S-8 As filed with the Securities and Exchange Commission on July 30, 2019 Registration No.
July 30, 2019	EX-24.1	POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that each of the undersigned, being a director or officer, or both, of Haemonetics Corporation (the “Company”), constitutes and appoints Christopher A. Simon, President and Chief Executive Officer, and Michelle L. Basil, Executive Vice President, General Counsel, and each of them, his or her true and lawful attorneys-in-fact and age
July 30, 2019	S-8	HAE / Haemonetics Corp. S-8 - - S-8 As filed with the Securities and Exchange Commission on July 30, 2019 Registration No.

HAE / Haemonetics Corporation - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)

Other Listings